Skip to content

The effect of Xingnao Yizhi acupuncture combined with Tongluo Kaiqiao mixture on urinary AD7c-NTP and serum inflammatory factors in cognitive impairment after stroke of Qi deficiency and blood stasis type

The effect of Xingnao Yizhi acupuncture combined with Tongluo Kaiqiao mixture on urinary AD7c-NTP and serum inflammatory factors in cognitive impairment after stroke of Qi deficiency and blood stasis type

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088177
Enrollment
Unknown
Registered
2024-08-13
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post stroke cognitive impairment, PSCI

Interventions

Observation group:Xingnao Yizhi Acupuncture Combined with Tongluo Kaiqiao Formula
control group:Oral administration of donepezil hydrochloride tablets

Sponsors

Mianyang Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of Western medicine PSCI and Traditional Chinese Medicine Qi Deficiency and Blood Stasis type shall be diagnosed through CT or MRI examination; (2) Age range from 40 to 75 years old, with a course of 3 to 6 months; (3) Mini Mental State Examination Scale (MMSE) score<24 points; The Montreal Cognitive Assessment (MoCA) score is less than 26 points, and if the tester has less than or equal to 12 years of education, an additional point can be added; (4) The patient did not have any cognitive impairment prior to onset; (5) The subjects are informed and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Complicated with intracranial hypertension, tumor, severe cardio pulmonary disease, hepatic and renal insufficiency and infectious diseases; (2) Cognitive impairment not caused by stroke; (3) Patients with poor compliance and visual, auditory, and speech impairments; (4) Patients who participate in = 2 clinical trials within 1 month; (5) Other situations that the researchers believe are not suitable for selection. If the patient meets any of the above criteria, the patient is not eligible to participate in this study.

Design outcomes

Primary

MeasureTime frame
Urinary Alzheimer's disease associated neurofilament proteins;Cognitive function scale;

Secondary

MeasureTime frame
Serum inflammatory factors;

Countries

China

Contacts

Public ContactSu Ling

Mianyang Traditional Chinese Medicine Hospital

2369862169@qq.com+86 189 8112 9261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026